Page 3 - emap_newsletter_V2
P. 3
eMAP – electronic EHA Medical HemAtology Program
The median progression-free survival (PFS) and event-free survival (EFS) were 9.0 months and 7.23 months, respectively. Among
patients who achieved CR, the median PFS and EFS were 22.60 months and 22.60 months, respectively. The median overall
survival (OS) has not been reached. The most frequent treatment-emergent adverse events (TEAEs) were neutropenia (51%),
fatigue (39%), and cytokine release syndrome (CRS, 38%), with the most common grade =3 TEAEs including neutropenia (48%),
leukopenia (21%), and thrombocytopenia (20%). There was only one patient (2%) with grade 3 CRS and no grade 4/5 CRS events.
Neurological events (NEs) were seen in 31% of patients, with grade 3 NEs occurring in only three patients (5%) and no grade 4/5
NEs.
The study authors concluded that liso-cel as second-line treatment in patients with R/R LBCL for whom HSCT was not intended
demonstrated substantial and durable responses, with no new safety concerns.
WATCH WATCH
DR. KURUVILLA’S IN-DEPTH PRESENTATION OF THIS DR. KURUVILLA’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~15 MINUTES) THESE DATA TO CANADIAN PRACTICE (~3 MINUTES)
CLICK HERE FOR THE LINK TO THE FULL ABSTRACT
Clinical and Patient-reported Outcomes in a Phase 3 Study of Axicabtagene
Ciloleucel (Axi-cel) vs. Standard-of-care in Elderly Patients with Relapsed/Refractory
Large B-cell Lymphoma (ZUMA-7)
Sureda A, et al. Presented at EHA 2022 Congress. Abstract S211.
Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-directed CAR T cell product that significantly improved
EFS compared with second-line SOC in patients with R/R LBCL in the phase 3, randomized ZUMA-7 study. Unfortunately,
older patients with R/R LBCL are at risk of inferior outcomes, increased toxicity, and inability to tolerate SOC treatment. The
objective of this planned subgroup analysis of the ZUMA-7 study was to assess the efficacy, safety, and patient-reported outcomes
(PROs) of second-line axi-cel vs. SOC in older patients aged =65 years.
TABLE OF CONTENTS 3
